Iterum Therapeutics (NASDAQ:ITRM) Receives Buy Rating from HC Wainwright
HC Wainwright restated their buy rating on shares of Iterum Therapeutics (NASDAQ:ITRM – Free Report) in a research report report published on Wednesday, Benzinga reports. They currently have a $6.00 price objective on the stock. Iterum Therapeutics Stock Up 17.8 % Shares of NASDAQ ITRM opened at $1.49 on Wednesday. The company has a quick […]
More Stories
Cheniere Energy Partners (CQP) & Its Competitors Financial Analysis
Cheniere Energy Partners (NYSE:CQP – Get Free Report) is one of 23 publicly-traded companies in the “Natural gas distribution” industry,...
Xos, Inc. (NASDAQ:XOS) Given Consensus Rating of “Moderate Buy” by Brokerages
Shares of Xos, Inc. (NASDAQ:XOS – Get Free Report) have earned a consensus rating of “Moderate Buy” from the six...
Oruka Therapeutics (NASDAQ:ORKA) & Myriad Genetics (NASDAQ:MYGN) Critical Review
Myriad Genetics (NASDAQ:MYGN – Get Free Report) and Oruka Therapeutics (NASDAQ:ORKA – Get Free Report) are both small-cap medical companies,...
AptarGroup, Inc. (NYSE:ATR) Receives $189.50 Average Target Price from Analysts
AptarGroup, Inc. (NYSE:ATR – Get Free Report) has been given an average rating of “Buy” by the seven analysts that...
Comparing VirTra (NASDAQ:VTSI) and Multi Ways (NYSE:MWG)
VirTra (NASDAQ:VTSI – Get Free Report) and Multi Ways (NYSE:MWG – Get Free Report) are both small-cap aerospace companies, but...
CAE Inc. (NYSE:CAE) Given Average Rating of “Hold” by Brokerages
CAE Inc. (NYSE:CAE – Get Free Report) (TSE:CAE) has earned an average recommendation of “Hold” from the nine brokerages that...